2019
Inhaled Iloprost Versus Epoprostenol in Heart Transplant Recipients
Enomoto TM, Treggiari MM, Yanez ND, Merkel MJ. Inhaled Iloprost Versus Epoprostenol in Heart Transplant Recipients. Respiratory Care 2019, 64: 743-751. PMID: 30967439, DOI: 10.4187/respcare.06426.Peer-Reviewed Original ResearchConceptsAcute right ventricular dysfunctionHeart transplant recipientsRight ventricular dysfunctionMechanical ventilationEnd pointHeart transplantationHospital stayTransplant recipientsVentricular dysfunctionHemodynamic valuesMedian numberAcute pulmonary hypertensionLength of ICUOrthotopic heart transplantationPrimary end pointSafety end pointSecondary end pointsImmediate postoperative periodPrimary vasodilatorVasoactive medicationsVasodilatory therapyPostoperative bleedingPulmonary hypertensionPostoperative periodConsecutive patients
2013
Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis
Mayer‐Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch‐Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW, for the EPIC E. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. Pediatric Pulmonology 2013, 48: 943-953. PMID: 23818295, PMCID: PMC4059359, DOI: 10.1002/ppul.22693.Peer-Reviewed Original ResearchConceptsTobramycin inhalation solutionHistorical controlsCystic fibrosisTrial participantsCulture positivityPA recurrenceDifferent antibiotic regimensHistorical control cohortInitial eradication therapyIncidence of hospitalizationStandard of careAntibiotic regimensEradication therapyRespiratory symptomsStandard careHospitalization outcomesHospitalization ratesCare treatmentControl cohortInhalation solutionAntimicrobial therapyClinical trialsEpidemiologic studiesInfection controlEligibility criteria
2011
Comparative Efficacy and Safety of 4 Randomized Regimens to Treat Early Pseudomonas aeruginosa Infection in Children With Cystic Fibrosis
Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Chatfield BA, Froh DK, Burns JL, Rosenfeld M, Ramsey BW, Investigators F. Comparative Efficacy and Safety of 4 Randomized Regimens to Treat Early Pseudomonas aeruginosa Infection in Children With Cystic Fibrosis. JAMA Pediatrics 2011, 165: 847-856. PMID: 21893650, PMCID: PMC3991697, DOI: 10.1001/archpediatrics.2011.136.Peer-Reviewed Original ResearchConceptsPseudomonas aeruginosa infectionCulture-based therapyCulture-based groupsCystic fibrosisAeruginosa infectionEarly Pseudomonas aeruginosa infectionTobramycin inhalation solutionPrimary end pointRate of exacerbationsExacerbation rateIntravenous antibioticsOral ciprofloxacinOral placeboAntibiotic regimensPulmonary exacerbationsAdverse eventsTreat analysisMulticenter trialAntipseudomonal treatmentInhalation solutionOdds ratioComparative efficacyPlaceboEnd pointFibrosis
2009
Atrial and brain natriuretic peptide concentrations and the response to inhaled nitric oxide in patients with acute respiratory distress syndrome
Treggiari MM, Bendjelid K, Yanez ND, Heidegger CP, Suter PM, Romand JA. Atrial and brain natriuretic peptide concentrations and the response to inhaled nitric oxide in patients with acute respiratory distress syndrome. Journal Of Critical Care 2009, 25: 23-29. PMID: 19327320, DOI: 10.1016/j.jcrc.2008.10.014.Peer-Reviewed Original ResearchConceptsAcute respiratory distress syndromeAtrial natriuretic peptideBaseline atrial natriuretic peptideRespiratory distress syndromeNT-proNatriuretic peptideBNP concentrationsDistress syndromeCardiac peptidesHigh atrial natriuretic peptideBrain natriuretic peptide concentrationsB-type natriuretic peptideNitric oxideCyclic guanosine monophosphate concentrationBaseline NT-proProspective cohort studyNatriuretic peptide concentrationsSubgroup of patientsCardiac natriuretic peptidesGuanosine monophosphate concentrationCyclic guanosine monophosphateIntrapulmonary shuntCohort studyConsecutive patientsClinical benefit